Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Gynecologic Oncology
•
Pediatric Hematology/Oncology
•
FAQ
•
Medical Oncology
Is there a Mednet app?
Answer from: Radiation Oncologist at Community Practice
theMednet app is here! Follow these links to download it for your iOS and Android devices.
Sign In
or
Register
to read more
Answer from: Radiation Oncologist at Community Practice
As more hospitals improve their WiFi, I envision attendings and residents co-reviewing comments from themednet in between patient visits. Looking forward to it.
Sign In
or
Register
to read more
1158
1166
Related Questions
What screening tools or signs do you use to predict if a cancer patient is near end-of-life?
What strategies do you find helpful in advanced care planning with patients/families who are very "miracle" centered?
In platinum-refractory or multiply-relapsed NSGCT with 1–2 progressive sites and no good surgical option, is there a role for local radiotherapy (e.g., SBRT) to those sites?
When utilizing KN-A18 protocol, how do you best address symptoms of colitis/cystitis?
Do you have concerns about the validity of the INTERLACE data, considering the long study recruitment period (10 years) and evolution of radiation techniques that have occurred during that time frame?
Does being on maintenance pembrolizumab change how you manage patients with partial metabolic response on PET/CT 3 months after chemoradiation for cervical cancer?
What are the best radiation therapy options for a young adult with 3 brain metastases from myeloid sarcoma that hasn’t responded well to intrathecal therapy?
In patients treated with the KEYNOTE A-18 regimen who later recur, would you rechallenge with immunotherapy again?
How have you incorporated ctDNA into the clinical management of patients with gynecologic cancers?
Would you offer systemic chemotherapy to a patient with at least 2023 FIGO stage IC high grade serous (p53-mut) endometrial cancer with extensive LVI for whom nodal assessment was not done?